NCT01752972

Brief Summary

Patients of arsenical keratosis may be treated with spirulina. Is this improvement related to the levels of zinc, vitamin E and linoleic acid at the site of the keratosis (palm)? To understand this, patients of palmer arsenical keratosis (n=10), arsenic exposed controls (n=10) and healthy volunteers (n=10) will be treated with spirulina powder 10 g/day orally for 12 weeks. Skin extracts will be collected both before and after supplementation from the palm and dorsum for estimation of zinc, vitamin E and linoleic acid levels.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2011

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2011

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

December 17, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 19, 2012

Completed
Last Updated

December 19, 2012

Status Verified

December 1, 2012

Enrollment Period

8 months

First QC Date

December 17, 2012

Last Update Submit

December 17, 2012

Conditions

Keywords

ArsenicKeratosisLinoleic acidPalmSpirulinaVitamin EZinc

Outcome Measures

Primary Outcomes (1)

  • Change in vitamin E levels in skin palm extract following supplementation with spirulina

    0 week (baseline), 12 weeks (end)

Secondary Outcomes (2)

  • Change in zinc levels in skin palm extract following supplementation with spirulina

    0 week (baseline), 12 weeks (end)

  • Change in linoleic acid levels in skin palm extract following supplementation with spirulina

    0 week (baseline), 12 weeks (end)

Study Arms (3)

Palmer arsenical keratosis

EXPERIMENTAL

Spirulina 10 g/day orally for 12 weeks

Dietary Supplement: Spirulina

Arsenic exposed controls

ACTIVE COMPARATOR

Spirulina 10 g/day orally for 12 weeks

Dietary Supplement: Spirulina

Heathy volunteers

ACTIVE COMPARATOR

Spirulina 10 g/day orally for 12 weeks

Dietary Supplement: Spirulina

Interventions

SpirulinaDIETARY_SUPPLEMENT

10 g/day orally for 12 weeks

Arsenic exposed controlsHeathy volunteersPalmer arsenical keratosis

Eligibility Criteria

Age20 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • moderate palmer keratosis
  • drink arsenic contaminated water (\>50 µg/L) for at least 6 months
  • voluntarily agree to participate
  • no symptoms of keratosis
  • family member of the patient
  • drink arsenic contaminated water (\>50 µg/L) for at least 6 months
  • voluntarily agree to participate
  • no symptoms of keratosis
  • drink arsenic safe water (\<50 µg/L)
  • voluntarily agree to participate

You may not qualify if:

  • pregnancy
  • lactation
  • chronic diseases: diabetes mellitus, rheumatoid arthritis, tuberculosis
  • arsenicosis patients under treatment in the previous 3 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bangabandhu Sheikh Mujib Medical University

Dhaka, Bangladesh

Location

MeSH Terms

Conditions

Keratosis

Condition Hierarchy (Ancestors)

Skin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Mir Misbahuddin, MBBS, PhD

    Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. and Chairman

Study Record Dates

First Submitted

December 17, 2012

First Posted

December 19, 2012

Study Start

April 1, 2011

Primary Completion

December 1, 2011

Study Completion

December 1, 2011

Last Updated

December 19, 2012

Record last verified: 2012-12

Locations